Cero Therapeutics Holdings, Inc

Cero Therapeutics Holdings, Inc (NASDAQ: CERO) is an immunotherapy company focused on developing engineered T cell therapies to combat cancer. Its unique engineering platform combines key features of both innate and adaptive immunity into a single therapeutic construct, aiming to harness the body’s entire immune system for more effective cancer treatment.

Positive Growth Aspects

• Advancing Clinical Development: The company made meaningful progress on its flagship candidate CER-1236, beginning clinical trials following the successful IND clearance. This transition from preclinical to clinical stage marks a critical milestone, moving the firm closer to potential regulatory approval and future commercialization.
• Strong Control of General Expenses: Despite higher clinical outlays, general and administrative expenses decreased to USD 4.0 million in the first half of 2025 from USD 5.3 million a year earlier, primarily due to reduced underwriting costs and lower executive salaries. This reduction demonstrates prudent cost discipline in areas outside of R&D, even as the company shoulders the additional expenses of operating as a public entity.
• Capital Raising Initiatives: CERo successfully secured funding through multiple financing activities, including PIPE transactions and warrant exercises, generating over USD 9 million in net proceeds in the first half of 2025. These efforts, while not eliminating funding challenges, provided essential liquidity to sustain operations and support clinical trial progress.
• Long-Term Growth Opportunities: The company continues to target high-value oncology markets with potentially transformative cell therapy solutions. Its R&D pipeline, combined with orphan drug designation strategies, positions it to potentially capture exclusivity advantages and establish a competitive edge if trials prove successful.

Growth Challenges

• Rising Research and Development Costs: R&D expenses rose significantly to USD 5.7 million in the first half of 2025, up 29% year-over-year, reflecting the onset of clinical trial activities and increased scientific consulting. While expected, this trend indicates higher cash burn rates that intensify funding requirements.
• Substantial Net Losses: The company reported a net loss of USD 10.5 million for the six months ended June 30, 2025, more than doubling the prior year’s USD 4.7 million. After accounting for deemed dividends tied to preferred stock conversions and warrant adjustments, net loss attributable to common stockholders soared to USD 35.6 million. This sharp increase underscores the strain on shareholder value.
• Material Weaknesses in Financial Controls: Management disclosed significant deficiencies in internal controls, including insufficient accounting expertise, weak processes for preferred stock transactions, and inadequate valuation documentation. These issues have already led to errors in financial reporting and delayed filings, raising concerns about governance and compliance.
• Going Concern Uncertainty: As of June 30, 2025, CERo held only USD 3.2 million in cash against an accumulated deficit of USD 81.4 million, with no revenue generation expected for several years. Management acknowledged “substantial doubt” about the company’s ability to continue as a going concern without securing significant additional financing, placing the future of ongoing clinical development at risk.

Technical Observation (on the daily chart):

Cero Therapeutics’ stock shows a sharp collapse from its late 2024 highs, followed by a prolonged downtrend and stabilization around the USD 4–USD 5 range. Both moving averages remain well above the current price, highlighting continued bearish sentiment, while the RSI at 21 indicates oversold conditions with limited signs of recovery. Low trading volumes further contribute to weak investor interest, suggesting the stock may stay range-bound unless a strong catalyst emerges.

Cero Therapeutics Holdings, Inc. delivered a quarter of both strategic progress and financial strain. On the positive side, the company advanced its lead program CER-1236 into Phase 1/1b clinical trials for AML, secured FDA clearance for additional indications, and demonstrated disciplined reductions in general and administrative expenses while successfully raising capital through financings to support operations. However, these achievements were overshadowed by rising R&D costs tied to clinical trial activities, a steep net loss of USD 35.6 million attributable to common shareholders, material weaknesses in financial controls, and significant going concern risks due to limited cash reserves and a growing accumulated deficit. This combination reflects a business making notable operational strides but facing persistent financial headwinds.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Watch’ rating has been given to Cero Therapeutics Holdings, Inc (NASDAQ: CERO) at the current market price of USD 4.74 as of September 9, 2025 at 10:40 am PDT. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is September 9, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.